drugset / Trial / NCT00774943

A Study of AMG 557 in Adults With Systemic Lupus Erythematosus

NCT00774943 ↗

Phase 1 Completed 58 enrolled Amgen
RandomizedFactorialTriple-blindTreatment

Summary

This is a Phase 1, randomized, placebo-controlled, double-blind, dose-escalation study of repeat SC doses of AMG 557 in adults with Systemic Lupus Erythematosus.

Timeline

Start
2008-12
Primary completion
2012-05
Completion
2012-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator AMG 557 Monoclonal antibody — Subcutaneous